EMA
- Application: EMEA/H/C/006579
- Marketing authorisation holder: Arrowhead Pharmaceuticals Ireland Limited
- Local brand name: Redemplo
- Indication: Treatment of familial chylomicronaemia syndrome (FCS).
- Pathway: orphan
- Status: approved
🇪🇺 Redemplo in European Union
Redemplo (PLOZASIRAN) regulatory status in European Union.
Marketing authorisation
Redemplo in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Metabolic approved in European Union
Frequently asked questions
Is Redemplo approved in European Union?
Yes. EMA has authorised it.
Who is the marketing authorisation holder for Redemplo in European Union?
Arrowhead Pharmaceuticals Ireland Limited holds the EU marketing authorisation.